We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
+42.82%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$417M
AUM Growth
+$95.9M
Cap. Flow
-$11.1M
Cap. Flow %
-2.67%
Top 10 Hldgs %
49.63%
Holding
82
New
7
Increased
14
Reduced
24
Closed
6
Avg Time Held
10.1 quarters
Top 10 Avg Time Held
5.4 quarters
Top 20 Avg Time Held
9.3 quarters

Top Buys

Rank Stock Value
1
SAGE icon
Sage Therapeutics
SAGE
+$4.86M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$4.37M
3
BHVN icon
Biohaven
BHVN
+$4.16M
4
SLRN icon
ACELYRIN
SLRN
+$3.11M
5
LKFT icon
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$2.58M

Top Sells

Rank Stock Value
1
BPMC icon
Blueprint Medicines
BPMC
+$8.98M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$6.02M
3
NRIX icon
Nurix Therapeutics
NRIX
+$4.38M
4
CYTK icon
Cytokinetics
CYTK
+$2.88M
5
AUTL icon
Autolus Therapeutics
AUTL
+$2.81M

Sector Composition

Rank Sector Weight
1 Healthcare 85.32%
2 Miscellaneous 14.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
XBI icon
1
State Street SPDR S&P Biotech ETF
XBI
$9.71B
$43.2M 10.36%
484,000
-81,000
-14% -$6.02M
2022 Q1
7 quarters
CYTK icon
2
Cytokinetics
CYTK
$8.57B
$33.4M 8%
400,000
-79,538
-17% -$2.88M
2021 Q3
9 quarters
STXS icon
3
Stereotaxis
STXS
$106M
$23.9M 5.74%
13,680,554
– –
2013 Q2
42 quarters
IDYA icon
4
IDEAYA Biosciences
IDYA
$3.31B
$18.4M 4.4%
516,341
+16,521
+3% +$493K
2020 Q3
13 quarters
SNDX icon
5
Syndax Pharmaceuticals
SNDX
$1.25B
$16M 3.85%
742,574
+284,201
+62% +$4.37M
2020 Q2
14 quarters
ASND icon
6
Ascendis Pharma A/S
ASND
$14.7B
$15.6M 3.73%
123,472
-12,740
-9% -$1.27M
2021 Q4
8 quarters
KRTX icon
7
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$15.2M 3.65%
48,145
-4,728
-9% -$919K
2020 Q1
15 quarters
RVMD icon
8
Revolution Medicines
RVMD
$40.4B
$14.7M 3.52%
511,894
+38,500
+8% +$925K
2020 Q4
12 quarters
IBB icon
9
iShares Biotechnology ETF
IBB
$10.2B
$13.9M 3.34%
102,500
– –
2016 Q4
28 quarters
XENE icon
10
Xenon Pharmaceuticals
XENE
$3.33B
$12.7M 3.05%
276,739
-3,799
-1% -$134K
2015 Q3
33 quarters
MRUS icon
11
DELISTED
Merus
MRUS
$12.5M 3%
454,870
-30,000
-6% -$701K
2021 Q1
11 quarters
BPMC icon
12
DELISTED
Blueprint Medicines
BPMC
$10.2M 2.45%
110,863
-138,658
-56% -$8.98M
2016 Q4
28 quarters
DAWN icon
13
DELISTED
Day One Biopharmaceuticals
DAWN
$10M 2.4%
686,463
+100,000
+17% +$1.21M
2023 Q2
2 quarters
NBIX icon
14
Neurocrine Biosciences
NBIX
$13.7B
$9.57M 2.29%
72,615
-1,000
-1% -$115K
2016 Q1
31 quarters
DXCM icon
15
DexCom
DXCM
$32.1B
$8.38M 2.01%
67,552
– –
2017 Q3
25 quarters
KALV icon
16
DELISTED
KalVista Pharmaceuticals
KALV
$7.36M 1.76%
601,032
-4,500
-0.7% -$40.9K
2021 Q1
11 quarters
BHVN icon
17
Biohaven
BHVN
$1.72B
$7.22M 1.73%
168,772
+133,772
+382% +$4.16M
2022 Q3
5 quarters
KURA icon
18
Kura Oncology
KURA
$874M
$7.08M 1.7%
492,684
-58,100
-11% -$571K
2017 Q3
25 quarters
MORF icon
19
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$6.69M 1.6%
231,748
– –
2020 Q4
12 quarters
TNDM icon
20
Tandem Diabetes Care
TNDM
$1.16B
$6.53M 1.56%
220,708
– –
2023 Q2
2 quarters
AXGN icon
21
Axogen
AXGN
$2.12B
$6.39M 1.53%
935,894
– –
2021 Q4
8 quarters
TSVT icon
22
DELISTED
2seventy bio
TSVT
$6.18M 1.48%
1,447,465
– –
2023 Q2
2 quarters
IMGN icon
23
DELISTED
Immunogen Inc
IMGN
$5.74M 1.38%
193,661
+110,661
+133% +$2.2M
2023 Q3
1 quarter
SAGE icon
24
DELISTED
Sage Therapeutics
SAGE
$5.31M 1.27%
+245,000
New +$4.86M
2023 Q4
0 quarters
LKFT icon
25
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.9B
$5.29M 1.27%
130,175
+70,000
+116% +$2.58M
2015 Q3
33 quarters
1
2 3 4

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, DAFNA Capital Management held 82 positions worth $417M, up 30% from $321M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

DAFNA Capital Management's Q4 2023 filing shows 7 new, 14 increased, 24 reduced and 6 closed positions. Its largest new stake was Sage Therapeutics: 245,000 shares worth $5.31M. The largest sale was Blueprint Medicines, an estimated $8.98M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 82% a quarter earlier, followed by Miscellaneous.

  • DAFNA Capital Management's largest Q4 2023 buy was Sage Therapeutics: 245,000 shares worth $5.31M.
  • DAFNA Capital Management added most to Syndax Pharmaceuticals in Q4 2023, an estimated $4.37M increase.
  • DAFNA Capital Management's biggest Q4 2023 reduction was Blueprint Medicines, cutting an estimated $8.98M.
  • DAFNA Capital Management fully exited Nurix Therapeutics in Q4 2023, selling an estimated $4.38M.
  • DAFNA Capital Management's ten largest holdings make up 50% of its $417M portfolio in Q4 2023.
  • DAFNA Capital Management opened 7 new positions and closed 6 in Q4 2023.
  • DAFNA Capital Management's portfolio value rose 30% quarter-over-quarter to $417M.

Based on DAFNA Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.